Investigation of the protective effects of dichloroacetic acid in a rat model of diabetic neuropathy

BMC Pharmacol Toxicol. 2025 Jan 22;26(1):15. doi: 10.1186/s40360-025-00849-8.

Abstract

Background: Diabetic neuropathy (DN) is a heterogeneous condition characterized by complex pathophysiological changes affecting both autonomic and somatic components of the nervous system. Inflammation and oxidative stress are recognized contributors to the pathogenesis of DN. This study aims to evaluate the therapeutic potential of dichloroacetic acid (DCA) in alleviating DN symptoms, focusing on its anti-inflammatory and antioxidant properties.

Methods: Thirty-two adult male Sprague Dawley rats were divided into four groups: Control, Diabetic, and two DCA-treated groups receiving 5 mg/kg and 10 mg/kg of DCA, respectively. Diabetes was induced with streptozotocin (STZ) injections. Assessments included lipid peroxidation levels, plasma fibroblast growth factor-21 (FGF-21) and transforming growth factor-beta (TGF-β) levels, electrophysiological measurements, histological examination of the sciatic nerve, and motor function tests.

Results: Treatment with DCA significantly reduced malondialdehyde (MDA) levels, indicating decreased lipid peroxidation. Plasma TGF-β levels were also lower in the DCA-treated groups, suggesting diminished inflammation. Conversely, plasma FGF-21 levels were elevated. Electrophysiological assessments revealed enhanced compound muscle action potential (CMAP) amplitudes and reduced distal latencies in DCA-treated rats, indicative of improved nerve conduction. Histopathological examinations showed reduced perineural thickness in the sciatic nerves of DCA-treated rats, pointing to decreased fibrosis. Enhanced performance in motor function tests was observed in these rats, implying improved muscle strength and motor capacity.

Conclusions: The study demonstrates that DCA therapy significantly reduces oxidative stress and inflammation in a rat model of DN, thereby ameliorating neuropathic symptoms. These results support the potential of DCA as a promising therapeutic agent for DN treatment. Further research is warranted to explore its clinical applications and to provide more detailed insights.

Keywords: Diabetes mellitus; Diabetic neuropathy; Dichloroacetic acid; Inflammation; Oxidative stress.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetic Neuropathies* / drug therapy
  • Dichloroacetic Acid* / pharmacology
  • Dichloroacetic Acid* / therapeutic use
  • Fibroblast Growth Factors / blood
  • Lipid Peroxidation / drug effects
  • Male
  • Malondialdehyde / blood
  • Malondialdehyde / metabolism
  • Neural Conduction / drug effects
  • Oxidative Stress / drug effects
  • Rats
  • Rats, Sprague-Dawley*
  • Sciatic Nerve / drug effects
  • Transforming Growth Factor beta / blood
  • Transforming Growth Factor beta / metabolism

Substances

  • Dichloroacetic Acid
  • Transforming Growth Factor beta
  • fibroblast growth factor 21
  • Fibroblast Growth Factors
  • Malondialdehyde
  • Antioxidants
  • Anti-Inflammatory Agents